Iqvia Hldgs Inc Stock Price, News & Analysis

IQVIA has partnered with Laboratoires Théa, a top independent eye care group in Europe, to implement its Orchestrated Customer Engagement (OCE) platform and the OneKey HCP/HCO reference database in over 22 markets. This collaboration aims to enhance Théa’s digital strategy and customer engagement, especially in the wake of changes prompted by the COVID-19 pandemic. The OCE platform integrates various functions to improve service delivery and relationships with healthcare professionals. IQVIA serves more than 125 life sciences companies with its innovative solutions.

Q² Solutions, a clinical trial laboratory services organization formed from an IQVIA and Quest Diagnostics joint venture, has partnered with Adaptive Biotechnologies to provide advanced immune-driven research services. The collaboration introduces immunoSEQ^® Assay and immunoSEQ^® T-MAP™ COVID, enhancing testing capabilities for pharma clients, particularly in understanding immune responses related to COVID-19 and drug development. This partnership is poised to improve the drug development lifecycle through detailed immune response analytics.

IQVIA (NYSE:IQV) has announced a collaboration with Servier to enhance its R&D clinical development processes through the SCORE program. This initiative aims to transform Servier's clinical trial applications and improve patient outcomes by utilizing optimized processes, data-driven insights, and innovative technology. Over the next two years, IQVIA will implement a robust program that leverages its expertise in R&D consulting, digital transformation, and technology solutions. The partnership is poised to address unmet medical needs and support Servier's ambitious growth plans.

IQVIA (NYSE: IQV) announced its support for the Real World Evidence Leadership Forum, uniting senior RWE executives from 18 pharmaceutical companies. This non-competitive group aims to address RWE challenges and enhance patient outcomes globally. Underlining the significance of real-world data, Dan Simpson of IQVIA stated that establishing trust in data usage is crucial. The forum's immediate focus includes fostering collaborative relationships between pharma and healthcare, promoting publications on trusted partnerships, and meeting biannually to tackle industry issues.

IQVIA announced that Zentiva is implementing its Orchestrated Customer Engagement (OCE) platform in 12 major markets. This partnership aims to enhance Zentiva's commercial operations and customer interactions. OCE will facilitate optimization of field processes and multi-channel marketing through AI/ML capabilities, benefiting sales and marketing teams. Paul Geymayer from Zentiva emphasized the importance of digitally enabling their teams to foster growth and efficiency.

IQVIA Holdings reported third-quarter 2020 revenue of $2,786 million, a slight increase of 0.6% year-over-year, with Technology & Analytics Solutions (TAS) revenue growing 10.2%. However, Research & Development Solutions (R&DS) revenue fell 4.5%, and Contract Sales & Medical Solutions (CSMS) dropped 13.9%. Adjusted EBITDA reached $604 million, up 1.9%. The company raised its 2020 revenue guidance to $11,100 - $11,250 million and provided a strong outlook for 2021, anticipating revenue between $12,300 million and $12,600 million.

IQVIA (NYSE: IQV) announces a partnership with the U.S. FDA to analyze data from its CARE Project COVID-19 registry. This project aims to gather insights on COVID-19 symptoms experienced by U.S. residents, regardless of diagnosis. Launched in April 2020, over 20,000 participants have enrolled, providing data on symptom severity and potential effects of medications and supplements. Nancy Dreyer, Chief Scientific Officer, emphasizes the project's focus on community-level insights and the role of various preventive agents, leveraging IQVIA's CORE technology for rapid analytics.

IQVIA Holdings Inc. (NYSE: IQV) will release its third-quarter financial results on October 20, 2020, before the market opens. Management will host a conference call at 9:00 a.m. ET on the same day, which can be accessed via the IQVIA Investor Relations website. Registration is required for participation, and a replay will be available shortly after the event. IQVIA specializes in analytics and technology solutions for the life sciences sector, employing around 67,000 individuals globally.